Cargando…

Selective Inhibitors of Histone Deacetylases 1 and 2 Synergize with Azacitidine in Acute Myeloid Leukemia

Acute myeloid leukemia (AML) is a heterogeneous group of hematopoietic stem cell disorders characterized by defects in myeloid differentiation and increased proliferation of neoplastic hematopoietic precursor cells. Outcomes for patients with AML remain poor, highlighting the need for novel treatmen...

Descripción completa

Detalles Bibliográficos
Autores principales:	Min, Chengyin, Moore, Nathan, Shearstone, Jeffrey R., Quayle, Steven N., Huang, Pengyu, van Duzer, John H., Jarpe, Matthew B., Jones, Simon S., Yang, Min
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Public Library of Science 2017
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5218480/ https://www.ncbi.nlm.nih.gov/pubmed/28060870 http://dx.doi.org/10.1371/journal.pone.0169128

Ejemplares similares

Chemical Inhibition of Histone Deacetylases 1 and 2 Induces Fetal Hemoglobin through Activation of GATA2
por: Shearstone, Jeffrey R., et al.
Publicado: (2016)

Histone deacetylase inhibitors induce apoptosis in myeloid leukemia by suppressing autophagy
por: Stankov, Metodi V., et al.
Publicado: (2013)

Epigenetic therapies in acute myeloid leukemia: the role of hypomethylating agents, histone deacetylase inhibitors and the combination of hypomethylating agents with histone deacetylase inhibitors
por: Xu, Qing-Yu, et al.
Publicado: (2020)

mTOR kinase inhibitors synergize with histone deacetylase inhibitors to kill B-cell acute lymphoblastic leukemia cells
por: Beagle, Brandon R., et al.
Publicado: (2014)

Selective HDAC inhibition by ACY-241 enhances the activity of paclitaxel in solid tumor models
por: Huang, Pengyu, et al.
Publicado: (2016)

Synergism of Heat Shock Protein 90 and Histone Deacetylase Inhibitors in Synovial Sarcoma
por: Nguyen, Anne, et al.
Publicado: (2009)

Roles of Histone Deacetylases in Acute Myeloid Leukemia With Fusion Proteins
por: Zhang, Juan, et al.
Publicado: (2021)

Histone Deacetylases and Histone Deacetylase Inhibitors in Neuroblastoma
por: Phimmachanh, Monica, et al.
Publicado: (2020)

Epigenetic Modifiers in Myeloid Malignancies: The Role of Histone Deacetylase Inhibitors
por: Ungerstedt, Johanna S.
Publicado: (2018)

The ubiquitin ligase RNF5 determines acute myeloid leukemia growth and susceptibility to histone deacetylase inhibitors
por: Khateb, Ali, et al.
Publicado: (2021)

A Case of Leukemia Cutis with Acute Myeloid Leukemia on Azacitidine Therapy
por: Kara, Asude, et al.
Publicado: (2017)

A Combined Histone Deacetylases Targeting Strategy to Overcome Venetoclax Plus Azacitidine Regimen Resistance in Acute Myeloid Leukaemia: Three Case Reports
por: Wang, Bin-Ru, et al.
Publicado: (2021)

Acadesine Circumvents Azacitidine Resistance in Myelodysplastic Syndrome and Acute Myeloid Leukemia
por: Cluzeau, Thomas, et al.
Publicado: (2019)

Regulatory Effects of Histone Deacetylase Inhibitors on Myeloid-Derived Suppressor Cells
por: Cui, Yudan, et al.
Publicado: (2021)

Venetoclax with Decitabine or Azacitidine in Relapsed or Refractory Acute Myeloid Leukemia
por: Bouligny, Ian M., et al.
Publicado: (2023)

The histone deacetylase inhibitor SAHA acts in synergism with fenretinide and doxorubicin to control growth of rhabdoid tumor cells
por: Kerl, Kornelius, et al.
Publicado: (2013)

Histone deacetylase inhibitors reduce differentiating osteoblast-mediated protection of acute myeloid leukemia cells from cytarabine
por: Sterner, Rosalie M., et al.
Publicado: (2017)

Gilteritinib Combined with Azacitidine as Salvage Therapy for B/Myeloid Mixed Phenotype Acute Leukemia
por: Horvat, Nathan P, et al.
Publicado: (2022)

The histone deacetylase inhibitor romidepsin synergizes with lenalidomide and enhances tumor cell death in T-cell lymphoma cell lines
por: Cosenza, Maria, et al.
Publicado: (2016)

Butyrate Histone Deacetylase Inhibitors
por: Steliou, Kosta, et al.
Publicado: (2012)

Systematic review of azacitidine regimens in myelodysplastic syndrome and acute myeloid leukemia
por: Shapiro, Roman M., et al.
Publicado: (2018)

Azacitidine-Induced Pneumonitis in a Patient With Acute Myeloid Leukemia and Hyperleukocytosis
por: Litvin, Rafaella, et al.
Publicado: (2022)

Radical surgery and venetoclax plus azacitidine in an octogenarian with acute myeloid leukemia
por: Ramdohr, Florian, et al.
Publicado: (2022)

Venetoclax with decitabine or azacitidine in the first‐line treatment of acute myeloid leukemia
por: Bouligny, Ian M., et al.
Publicado: (2023)

Histone Deacetylases and Histone Deacetylase Inhibitors: Molecular Mechanisms of Action in Various Cancers
por: Sanaei, Masumeh, et al.
Publicado: (2019)

Mutant Isocitrate Dehydrogenase 1 Inhibitor Ivosidenib in Combination With Azacitidine for Newly Diagnosed Acute Myeloid Leukemia
por: DiNardo, Courtney D., et al.
Publicado: (2021)

Antileukemic activity and mechanism of action of the novel PI3K and histone deacetylase dual inhibitor CUDC-907 in acute myeloid leukemia
por: Li, Xinyu, et al.
Publicado: (2019)

Azacitidine in 302 patients with WHO-defined acute myeloid leukemia: results from the Austrian Azacitidine Registry of the AGMT-Study Group
por: Pleyer, Lisa, et al.
Publicado: (2014)

Venetoclax and azacitidine compared with induction chemotherapy for newly diagnosed patients with acute myeloid leukemia
por: Cherry, Evan M., et al.
Publicado: (2021)

Pharmocologic treatment with histone deacetylase 6 inhibitor (ACY-738) recovers Alzheimer's disease phenotype in amyloid precursor protein/presenilin 1 (APP/PS1) mice
por: Majid, Tabassum, et al.
Publicado: (2015)

A Comparison of Azacitidine and Decitabine Activities in Acute Myeloid Leukemia Cell Lines
por: Hollenbach, Paul W., et al.
Publicado: (2010)

Azacitidine as Salvage Therapy for Acute Myeloid Leukemia in a Severely Ill Patient
por: Powers, Harry Ross, et al.
Publicado: (2014)

Impact of TP53 mutations in acute myeloid leukemia patients treated with azacitidine
por: Bories, Pierre, et al.
Publicado: (2020)

Cost-effectiveness analysis of oral azacitidine maintenance therapy in acute myeloid leukemia
por: Bewersdorf, Jan Philipp, et al.
Publicado: (2021)

Synergistic activity of IDH1 inhibitor BAY1436032 with azacitidine in IDH1 mutant acute myeloid leukemia
por: Chaturvedi, Anuhar, et al.
Publicado: (2020)

Histone deacetylase inhibitors in multiple myeloma
por: Deleu, Sarah, et al.
Publicado: (2009)

Histone deacetylase inhibitors in Hodgkin lymphoma
por: Buglio, Daniela, et al.
Publicado: (2010)

Clinical Toxicities of Histone Deacetylase Inhibitors
por: Subramanian, Srividya, et al.
Publicado: (2010)

Acetylation and Histone Deacetylase Inhibitors in Cancer
por: Kortenhorst, Madeleine S. Q., et al.
Publicado: (2006)

Histone Deacetylase Inhibitors as Anticancer Drugs
por: Eckschlager, Tomas, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_l2dplgngoa559n108l5nd13kg8